Our team has reviewed 14 papers on #COVID vaccine phase 1-3 trials, including those produced by @moderna_tx, @BioNTech_Group/@pfizer,& @OxfordVacGroup/@AstraZeneca. All results to date have shown that the vaccines are safe and have very few side effects, including in older adults Phase 1 trials focus on safety & finding the appropriate dose. Phase 2 trials study safety & immune response. Phase 3 trials also investigate safety & test vaccine efficacy. One key is that all 3 phases examine safety & build on each other to guarantee the safest vaccine possible

Are individuals with psychiatric diagnoses at greater risk of #COVID19? And what are the psychiatric consequences of COVID-19 disease? This study investigated the bidirectional relationship between COVID-19 and psychiatric diagnoses using a large, representative cohort in the US. In @TheLancetPsych, Taquet et al created two cohorts (adults with and without psychiatric diagnosis in the past year) using the @TriNetX Research Network, which includes electronic health records for 70 million patients across 54 US health care centers. bit.ly/3nCYVxX

We reviewed the first analysis of mortality among patients receiving #ConvalescentPlasma therapy from #COVID19 survivors through the US Expanded Access Program. The effect of #ConvalescentPlasma on #COVID19 mortality has not previously been well described bit.ly/3gpFGDn In full disclosure, the lead author is based at Hopkins; however, none of the NCRC reviewers were direct collaborators. Thus, the article had an independent external review by someone without current or past professional collaborations with the author and no Hopkins affiliation.

What evidence has the @JHSPH_NCRC reviewed to date on treatments for COVID-19? 💊💉🩸 From Gautret et al. in International Journal of Antimicrobial Agents:
Viral shedding appeared lower in the #hydroxychloroquine arm; however, important differences between groups may also explain the effect seen. bit.ly/2W5meov